NCT02431767View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 8, 2017

Study Completion Date

December 20, 2017

Conditions
HIV Infections
Interventions
BIOLOGICAL

PENNVAX®-GP HIV-1 DNA vaccine

Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

BIOLOGICAL

Interleukin-12 (IL-12) DNA adjuvant

Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

BIOLOGICAL

Placebo

Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.

Trial Locations (4)

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

37232-2582

Vanderbilt Vaccine (VV) CRS, Nashville

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02431767 - Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults | Biotech Hunter | Biotech Hunter